FDA approves Teal Wand — first at-home test to screen for cervical cancer
The Food and Drug Administration has approved the first at-home test for cervical cancer screening, its maker Teal Health said on Friday, offering an alternative to Pap smears that need to be undertaken at a doctor's office.
Pap smear tests have significantly reduced cancer incidence from when they were first introduced 80 years ago. But they can be uncomfortable due to the requirement for an in-clinic exam.
Teal Health said the FDA's decision was based on a study in more than 600 women that showed self-collected samples using its test had the same performance as clinician-collected samples.
3 Regulators approved the first at-home test for cervical cancer screening, its maker Teal Health said, offering an alternative to Pap smears that need to be undertaken at a doctor's office.
Teal Health/AFP via Getty Images
The approval is 'not just about an innovative new product, it's about finally giving women an option that makes sense for their lives — something that can be done quickly and comfortably at home,' said Teal's co-founder and CEO Kara Egan.
Each year in the US, about 11,500 new cases of cervical cancer are diagnosed and about 4,000 women die of this, according to the Centers for Disease Control and Prevention.
The startup's test, Teal Wand, detects human papillomavirus (HPV), which is responsible for nearly all cervical cancers, similar to Roche's cobas HPV test. But Teal Wand allows women to collect samples from home and send it to a certified lab for testing, while Roche's test is approved for use in the clinic.
Teal Health did not disclose the test's price, but said it was working with major insurance providers for coverage and flexible payment options.
3 Teal Wand allows women to collect samples from home and send it to a certified lab for testing.
Teal Health/AFP via Getty Images
3 Teal Health said the FDA's decision was based on a study in more than 600 women that showed self-collected samples using its test had the same performance as clinician-collected samples.
AP
Egan pointed to another at-home test called Cologuard, made by Exact Sciences, to detect colon cancer.
'So Cologuard (is) fully covered by most insurance, but also, if you have to pay out pocket, it's around $600. We plan to be less than that,' she told Reuters.
Teal Health plans to begin rolling out the kits in June for patients aged 25 to 65 years.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology VSTM shares rallied 22.2% in a month, primarily driven by the FDA approval of the company's novel combination regimen of avutometinib plus defactinib in early May for treating KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC), a rare and distinct type of ovarian cancer. The FDA's decision came well in advance of the originally expected date of June 30, 2025. The approval was granted under the FDA's accelerated approval pathway and is commercialized in the U.S. market as an oral combination co-pack with the two prescription products, known as 'Avmapki Fakzynja Co-Pack.' Following the FDA approval, Avmapki Fakzynja Co-Pack is the first and only FDA-approved treatment for the LGSOC indication. Per Verastem Oncology, the combo offers a much-needed treatment option for patients and sets a new standard of care for women with recurrent LGSOC with a KRAS mutation. Full approval of the product for this use depends on the detailed evidence of clinical benefit in the follow-up phase III RAMP 301 confirmatory study, which will evaluate the combination in women with and without a KRAS mutation. Year to date, Verastem Oncology stock has surged 64.8% against the industry's 5.8% decline. Image Source: Zacks Investment Research Please note that the FDA's decision was based on the results from VSTM's phase II RAMP 201 study, which evaluated the combination of Avmapki and Fakzynja in adult patients with measurable KRAS-mutated recurrent LGSOC. Per the data readout, a 44% overall response rate was observed in patients treated with the combo therapy, with an acceptable safety profile. Additionally, the median duration of response ranged from 3.3 to 31.1 months in the KRAS mutant population. The Avmapki/Fakzynja combo enjoys the FDA's Breakthrough Therapy designation for the treatment of patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in the United States. Avutometinib alone or in combination with defactinib also enjoys the FDA's Orphan Drug designation for the same indication. Verastem Oncology is also looking to expand the label of its approved avutometinib/defactinib combo therapy beyond LGSOC. Last week, VSTM reported positive updated safety and efficacy results from the phase I/II RAMP 205 study evaluating avutometinib plus defactinib in combination with chemotherapy (gemcitabine and Nab-paclitaxel) for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) patients. This has also likely contributed to the stock price rally in the past month. The RAMP 205 study is evaluating 60 patients in five cohorts (12 per cohort) who are receiving one of five dose regimens of avutometinib/defactinib combo with chemotherapy for frontline metastatic PDAC. As of April 25, 2025, patients in the dose level 1 cohort achieved an overall response rate of 83% (eight confirmed and two unconfirmed who remain on treatment). Based on this encouraging outcome, Verastem Oncology selected dose level 1 as the recommended phase II dose. Additionally, it was found that the dose level 1 showed the best response, and overall, 92% of patients across all dose levels achieved tumor shrinkage. The safety profile of the avutometinib/defactinib combo was acceptable across all the treatment cohorts and no new safety signals were identified. Verastem Oncology is currently gearing up to initiate a registrational phase III front-line metastatic PDAC study in 2026. Apart from these indications, the company is simultaneously evaluating avutometinib and defactinib in combination with a KRAS G12C inhibitor, sotorasib, for treating non-small cell lung cancer in a separate mid-stage study. Verastem, Inc. price-consensus-chart | Verastem, Inc. Quote Verastem Oncology currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Bayer BAYRY, Lexicon Pharmaceuticals LXRX and Amarin AMRN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Bayer's earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 45.3%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. In the past 60 days, estimates for Lexicon's loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 6.6%. LXRX's earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%. In the past 60 days, estimates for Amarin's loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 17.1%. AMRN's earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Lexicon Pharmaceuticals, Inc. (LXRX) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Verastem, Inc. (VSTM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
FDA Expands Cucumber Recall Amid Salmonella Outbreak
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."Cucumber recall expands amid Salmonella outbreak. Bedner Growers Inc. cucumbers included in products by various brands are now being recalled. Below, find a list of impacted products. Last month's cucumber recall is expanding amid a Salmonella outbreak. The U.S. Food and Drug Administration (FDA) recently updated the products associated with the original Bedner Growers, Inc. recall to include products that either use the recalled cucumbers in their ingredients or feature the cucumbers under new packaging. According to updated statements shared by the FDA on May 28, 2025, and June 4, 2025, the initial Bedner Growers Inc. recall now also includes the following items (full UPC codes and best-by dates can be found in the initial recall statements): Mai sushi—various sushi rolls and boxes Kings, Isabelle's Kitchen Inc., Maple Avenue Foods—prepackaged salads Supreme Produce—fresh-cut salad and vegetable trays Snowfruit & Snowfox—fresh-cut cucumbers and sushi East Coast Fresh, TOPS, Wellsley Farms, Weis, Ahold, Jack and Olive, Created Fresh, Spring and Sprout—Salads, salsas, and other products that include the salsa made with Bedner Growers cucumbers PennRose Farms—whole cucumbers Marketside—fresh-cut cucumbers Read to Eat and Star Market—Greek salad Ukrop's—marinated cucumber salad Big Y Foods—made-to-order sandwiches, wraps, and paninis TGD Cuts—salsa, hot 6/12 oz. TGD Cuts—salsa, mild 6/12 oz. TGD Cuts—salsa, mild 5lb. TGD Cuts—salsa, mild 5lb. TGD Cuts—cucumber sliced/grape tomato 50/2oz. TGD Cuts—cucumber sliced unpeeled 5lb. TGD Cuts—cucumber sliced unpeeled 50/2oz. TGD Cuts—cucumber spears 50/2oz. These products were sold under various brand names, including Jenny's Classic, Mia, Supreme Produce, and more, at big chain stores like Walmart and Target (see here for a comprehensive list of impacted products), as well as smaller chains, nationwide. According to the original recall statement, the cucumbers from sampling tested positive for Salmonella Montevido. Additional samples taken at the same time and location also came back positive for other strains that the FDA believes are unrelated to the current outbreak that, as of press time, have sickened 45 and sent 16 to the hospital. According to the Mayo Clinic, symptoms of a salmonella infection—also known as salmonellosis, and involves the intestinal tract—may range from mild to severe. While some people who develop salmonellosis may have no symptoms at all, others may experience more moderate symptoms, which may include diarrhea, stomach cramps, and fever. Those with more severe symptoms may experience dehydration as a result of the infection, which can require medical attention. While rare, some can experience life-threatening complications, which typically occur when the Salmonella infection moves beyond the intestines and into other parts of the body. Most people do not need to seek medical attention for a Salmonella infection, however, there are times when you should call your healthcare provider. For example, if you experience symptoms that last longer than just a few days, develop a fever, or begin to notice signs of dehydration, you should reach out to your medical provider at once. The FDA urges consumers not to eat any product that they suspect is a part of the recall. Instead, safely dispose of it or return it to the point of purchase. If you have questions about this recall and your personal medical risk, you should contact your doctor for more information. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
3 hours ago
- Yahoo
For The Best Mayo-Free Tuna Salad Reach For This Creamy Ingredient Instead
Americans have long considered tuna salad a healthy meal, thanks in part to tuna's important nutrients like protein and calcium. Canned tuna also means it's easy to make. But tuna salad's reputation as a simple diet food can be undermined by one common ingredient: mayonnaise. Whether for health reasons or personal preference, Greek yogurt makes a great substitute in tuna salad. Greek yogurt is significantly lower in sodium, calories, fat, and cholesterol than mayonnaise, which contains at least 65% vegetable oil per FDA regulations. Greek yogurt's similarly creamy texture will help hold the salad together, and although it doesn't taste like mayo, the tart tanginess of Greek yogurt is also great for letting tuna and other ingredients shine. Greek yogurt is also a particularly nutritious addition. It contains vitamin B12, which boosts nervous system function, as well as selenium and zinc, two elements that are important for a healthy immune system. It's also notably high in protein, further boosting the already protein-rich nature of this food. Read more: 14 Condiments That Don't Need To Be Refrigerated It's possible to freeze tuna salad for up to two months if you use full-fat Greek yogurt. Mayonnaise and low-fat Greek yogurt are both prone to separating when frozen, which can ruin the texture. Full-fat is thicker, which helps maintain creaminess when thawed. And though it's high in fat, they are healthy fats associated with a lower risk of diabetes and higher HDL cholesterol (the good kind). A tip for a better-tasting tuna salad is to drain canned tuna first, whether it is eaten fresh or frozen. Removing excess oil or brine from the tuna will help the Greek yogurt stick better, creating improved consistency. When freezing the tuna salad, that excess liquid could lead to the formation of ice crystals and freezer burn, so it's best to leave it out. Like full-fat Greek yogurt, many unexpected tuna salad ingredient additions freeze well when stored correctly in an airtight container, including chickpeas and jalapeños. But other potential components may soften after freezing, including conventional ones like celery and tomatoes, as well as unconventional choices like kimchi and apples. Hungry for more? Sign up for the free Daily Meal newsletter for delicious recipes, cooking tips, kitchen hacks, and more, delivered straight to your inbox. Read the original article on The Daily Meal.
